Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer (MIBC) is a type of bladder cancer that has spread into the muscle layer of the bladder wall, making it more serious and often requiring more aggressive treatment.
Muscle-Invasive Bladder Cancer: Erdafitinib Treatment Study
We are studying the effects of erdafitinib alone and with cetrelimab in patients with muscle-invasive bladder cancer who cannot take cisplatin. The goal is to see if this treatment can shrink tumors before surgery.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a confirmed diagnosis of muscle-invasive bladder cancer (MIBC)?
- Are you currently pregnant or breastfeeding?
- Have you had major surgery in the past 14 days?
- Are you taking any medications that suppress your immune system, like steroids or other immunosuppressants?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Jnj-63723283
Jnj-42756493
Cetrelimab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Jean Perrin
Oncology
Beaumont, France
Institut Mutualiste Montsouris
Medical Oncology
Gentilly, France
Centre Leon Berard
Medical Oncology
Meyzieu, France
Sponsor: Grupo Espanol De Oncologia Genitourinaria-Socug
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.